What top creators are saying about Sarepta Therapeutics, Inc.(SRPT)— Page 2

The speaker is extremely bearish, raising significant safety concerns about the company's gene therapy products, calling it a 'Piece of shit' and noting the stock price is stagnant.

The speaker is long the stock, viewing it as a 'good value play'. The investment is described as a 'slog', suggesting it is a long-term holding that requires patience and should be part of a diversified portfolio.

This is the speaker's biggest long position (10% of portfolio), held with high conviction for its long-term recovery potential despite recent poor stock performance.

The speaker is very bullish, holding a large 10% portfolio position. He believes the company's LGMD drug alone could be worth more than the entire current market cap.